Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings

Timeline

Key events during the development of the guidance

Date Update
20 November 2013 Guideline published - CG173 Neuropathic pain - pharmacological management
18 July 2013 Consultation on the draft of the guideline is complete and the guideline is being modified in the light of comments received.
18 June 2013 The draft guideline is out for consultation with stakeholders. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.
03 August 2012 The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the NCCs will accept relevant confidential data for consideration by the GDG.
June 2012 The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.
23 March 2012 NICE will fully update its clinical guideline on the pharmacological management of neuropathic pain in non-specialist settings in order to address ongoing uncertainties regarding the cost effectiveness of some of the recommended treatment options. The planned update is not related to the safety or clinical efficacy of the drugs. Until a further announcement is made, the original guideline (CG96) continues to represent best practice for the NHS.